Cooper Companies: A Long-Term Value Investing Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging an existing pie, or creating an entirely new market?5/10

  A

  The ceiling is big enough and long enough, but in essence this is "enlarging, deepening, and upgrading a large pie that already exists" rather than conjuring an entirely new market out of thin air; this is exactly the kind of "growth within maturity" that Baillie Gifford's LTGG is most wary of.

  First, the pie itself. Cooper's truly good asset, CooperVision, sells soft contact lenses, a mature category that has existed for decades: the global contact-lens market was roughly around $12 billion in 2025, split among four oligopolists (Johnson & Johnson Vision, Alcon, CooperVision, and Bausch + Lomb), with the top three together holding about 65% share. In other words, the demand for vision correction was satisfied long ago; Cooper is not educating a nonexistent demand, but grabbing share and lifting per-customer price in a mature race with a relatively concentrated profit pool and a fixed set of players. The report is honest about this too: CooperVision's 2026 Q1 growth "came mainly from gains in silicone-hydrogel market share", a textbook case of "enlarging its own slice of the existing pie," not opening new frontiers.

  Only one piece truly carries a "creating a new market" flavor: pediatric myopia management. This is the closest thing in Cooper's hands to an "entirely new pie." Its MiSight 1 day is, as the report discloses, "the first and only product approved by the FDA in the U.S. to slow the progression of myopia in children," and it has also been approved in China and Japan; clinically, MiSight slowed myopia progression by an average of 59% and axial elongation by 57% in children aged 8–12. And the demand-side runway is extremely steep: global myopia prevalence is projected to rise from about 30% to nearly 50% by 2050 (about 5 billion people), and the BJO/BMJ estimate cited in the report also approaches 40% by 2050. This myopia-management niche is indeed "creating" a treatment market that did not exist before: parents used to be able only to correct their children with ordinary glasses, and now there is a brand-new demand for "slowing progression." The problem is that it is still a relatively small piece of the whole business; the overall myopia-control-lens market is currently only at the billion-dollar level, unable to support the ceiling narrative for the entire company.

  The other leg, CooperSurgical (women's health, assisted-reproduction consumables and services, genetic testing), sits in the infertility field, whose demand side is likewise favorable over the long run: the WHO says roughly one in six people of reproductive age worldwide will experience infertility at some point in their lives. But this business is more fragmented, bears heavy M&A fingerprints, and has poor return quality, and the company launched a formal strategic review in December 2025 and is in talks with multiple parties to sell CooperSurgical, so from a "future ceiling" standpoint, this leg may well no longer belong to Cooper.

  Conclusion: the ceiling is high enough (vision correction + myopia control + global penetration) and the runway is long, but the vast majority of growth comes from "grabbing share in a large mature market, upgrading categories, and expanding regionally," and the only truly creative part is the small but steep niche of pediatric myopia management. This is a good business that can be steadily scaled up, but it is not the kind of disruptive growth stock Baillie Gifford favors that "breaks new ground and redefines an industry."

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  Almost impossible. Doubling revenue over the next five years implies a compound annual growth rate of about 15%, but Cooper's real growth rate, past and present, is only about half that, and the growth mix is dominated by volume and share, lacking an engine that could accelerate it to a doubling.

  First, calibrate how fast it runs today with first-hand data. The report records FY2025 total revenue of about $4.092 billion and a four-year compound growth rate "near high single digits"; the latest quarter confirms this pace: FY2026 Q2 total revenue was $1.082 billion, up 8% year over year, with organic growth of +5%, of which CooperVision was $723.5 million (+8%) and CooperSurgical $358.0 million (+8%). The company's own FY2026 full-year guidance is revenue of $4.285–4.321 billion, with organic growth of 3.5%–4.5%. In other words, the organic growth the company itself plans for is mid-single digits; even "up 50% in five years" would take effort, an order of magnitude short of "doubling."

  What drives growth? Broken down, none of the three sources can single-handedly pull the curve to a doubling:

  • Volume + share (the mainstay). The report explicitly writes that CooperVision's growth is driven by "gains in silicone-hydrogel market share": taking share from rivals and lifting volume through dailies and complex-lens penetration. This is steady, but in an oligopoly, taking share is incremental; the top three already hold about 65%, and there is no room to grab 10 points in a single year.

  • Price. Contact lenses have a modest category-upgrade premium (ordinary → silicone hydrogel → high-end myopia-management lenses), and gross margin has long held steady around Q2's 68%, indicating pricing power; but this is "moderate, not unlimited pricing power," contributing a few points rather than a doubling in magnitude.

  • New businesses (fastest but smallest). The truly high-speed line is pediatric myopia management (MiSight), which enjoys the roughly 16%-level high growth of myopia-control lenses and the long runway of myopia prevalence approaching 50% by 2050, but its base is too small to move the whole book.

  Worse still is a structural headwind: the company is pushing to sell CooperSurgical (about one-third of FY2025 revenue). Once divested, for the remaining CooperVision standalone to grow from about $2.8 billion over five years to "double" the entire original book to over $8 billion is even more of a fantasy; after divestiture, the denominator of the "doubling" question itself changes, and pure organic growth cannot reach it. The M&A engine that boosted revenue in the past (per the report, buying certain Cook Medical assets for $300 million in 2023 and obp Surgical for $100 million in 2024) also mainly served the Surgical side, and after divestiture this bolt-on channel likewise narrows.

  Conclusion: doubling over the next five years is unrealistic; a reasonable expectation is mid-single-digit organic growth, driven mainly by volume + share, aided by modest price increases and the new myopia-management business. This is a reliable compounding business, but not an explosive growth stock that can double in five years; this is exactly why the report gives "Watch" rather than "Buy," with an expected annualized return of only 5%–7% in the base scenario.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  A second growth curve does exist today and is visible, but it is more like a "high-end extension of the main curve" than an independent new engine started from scratch; at the same time, a dramatic variable has just emerged: the company may well reshape its growth structure by selling CooperSurgical.

  First, the takeover candidate already running today: pediatric myopia management (MiSight). This is the most genuine "second curve" in Cooper's hands: it enjoys a demand runway independent of mature vision correction (global myopia prevalence will climb toward nearly 50% by 2050), has a real moat (MiSight 1 day is the first and only FDA-approved product in the U.S. to slow the progression of myopia in children, clinically slowing progression by 59%, and has been approved in China and Japan), and grows far faster than the core business (the myopia-control-lens niche compounds at roughly the 16% level). But to be honest about its limits: it is still in essence "selling contact lenses to a new population (children)," a category extension of CooperVision's main curve that shares the same manufacturing and channels, not a paradigm-different second engine that can independently backstop the business if the core stalls; and the myopia-control-lens market is currently still at the billion-dollar level, a base too small to shoulder the burden of "taking over the whole book."

  The second candidate, assisted reproduction and women's health (CooperSurgical), was once treated as a diversification growth pole, and its demand side does have a long runway (the WHO says roughly one in six people of reproductive age worldwide will experience infertility at some point in their lives). But it is precisely the weak side the report criticizes throughout: fragmented, heavy with M&A fingerprints, poor return quality, with FY2025 operating profit recorded by the report at only $43.4 million.

  The truly new situation is this: this "second curve" is today facing divestiture. The company launched a formal strategic review in December 2025 and is in talks with multiple parties to sell CooperSurgical, leaning toward an outright sale. In other words, the company's answer is the opposite: it is not nurturing a second curve, but preparing to cut off the lagging leg and converge into a purer vision-health company. If the sale is completed, most of the proceeds will likely go to buybacks, realizing returns through per-share value rather than new businesses.

  So the honest judgment is: five years out, the one taking over is unlikely to be some brand-new business, but rather "myopia management + silicone-hydrogel premiumization" continuing to push CooperVision's main curve upward; this is an extension, not a revolution. The "independent second curve that exists today and can carry the flag tomorrow" that Baillie Gifford looks for is, strictly speaking, not something Cooper has; it is more a steady company deepening its core while actively subtracting (divesting Surgical) to improve capital-return quality, rather than a growth stock achieving a nonlinear leap via a new engine.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  The core competitive advantage is concentrated on the CooperVision side: brand and clinical trust + massive SKU/parameter coverage + manufacturing process + global channels + switching costs after a successful fit + regulatory-approval barriers; over the next three to five years this moat will most likely "slowly widen," but the widening comes from structural upgrades, not the self-reinforcing hard moat of network effects.

  First, quantify the moat's real strength. Cooper sits in a good, oligopolistic race: the global contact-lens market is dominated by four players, Johnson & Johnson Vision, Alcon, CooperVision, and Bausch + Lomb, with the top three together holding about 65%, and barriers to entry are not low; silicone-hydrogel lenses depend heavily on complex manufacturing processes and key raw materials (the report specifically flags silicone-hydrogel raw-material supply, tariff, and logistics risks in its risk factors). This "concentrated profit pool that new entrants struggle to shake" structure is itself the base of the moat. Profitability also confirms pricing power: FY2026 Q2 gross margin was about 68%, and non-GAAP operating margin was about 27%, up 260 basis points year over year, showing it is expanding margins even while taking share, so the pricing power is real (though the report judges it "moderate, not unlimited").

  The two hardest parts of the moat are switching costs and regulatory approval: once complex lenses (astigmatism, presbyopia, myopia management) are successfully fitted, both patients and doctors are reluctant to switch frequently; the report judges this "moderate-to-strong." And MiSight, as the only FDA-approved pediatric myopia-management lens in the U.S., creates a real approval first-mover and label-exclusivity advantage. But to be honest: on network effects the report explicitly judges "weak"; this is not a platform business, share is grabbed inch by inch through products and channels, and it does not snowball automatically.

  Widen or narrow? My judgment is a mild widening, coming mainly from three directions: first, silicone-hydrogel penetration keeps rising, and the report records Cooper's growth as driven precisely by "gains in silicone-hydrogel share"; second, the high-complexity, high-stickiness category of pediatric myopia management scaling up, with a demand-side long runway of myopia prevalence approaching 50% by 2050, where high-end lens mix upgrades lift per-customer value and switching costs; third, the company just completed its 10th consecutive quarter of beating expectations, with both segments up 8% in Q2, showing execution is not losing share.

  A variable that lowers the moat's "narrowing risk" while raising its purity: the company is pushing to sell the weaker CooperSurgical. The report already judges Surgical's moat as "softer"; its barriers are product portfolio + channel relationships rather than hard assets. After divestiture, what remains will be the CooperVision standalone with the hardest moat, and the company's overall moat "average purity" will rise, but at the cost of a narrower ceiling and no more of Surgical's diversification leg.

  Conclusion: this is a moat that genuinely exists, concentrated in the contact-lens business, slowly widening over the next 3–5 years, driven by structural upgrades and myopia management rather than network effects or winner-take-all. It is enough to support steady compounding and decent pricing power, but it is not the "bigger is stronger" type of moat that self-reinforces exponentially with scale; the widening is incremental and must be continually defended through manufacturing and clinical execution.

  Jun 11, 2026
• QIf its core business were disrupted, does it have the DNA to reinvent itself? How does it treat mistakes and bad news?4/10

  A

  Cooper is not the kind of company that wins on "self-disruption DNA," and its core business is not easily disrupted overnight; but it just went through a textbook real-world test of "how to treat mistakes and bad news": CooperSurgical's embryo-culture-medium recall. Its performance was "pragmatic and decisive in the aftermath handling, but with a hard flaw in pre-event quality control," overall above passing, but hardly excellent.

  First, answer "does it have the DNA to reinvent itself when disrupted." Honestly, this company's strengths are incremental process iteration and M&A integration, not disruptive self-reinvention. Its moat is defended inch by inch through manufacturing, clinical trust, and channels, with the report judging network effects "weak" and capital-allocation capability "average." The risk of genuine technological substitution is in fact low; contact lenses being replaced by refractive surgery, intraocular lenses, and the like is a slow long-term trend, not a disruption hanging overhead. So the "reinvention DNA" question is not as life-or-death for Cooper; but conversely, if one day the core business really is replaced by a paradigm-level technology, its past trajectory shows it is more likely to buy new capabilities through M&A than to incubate a disruptive second curve internally; this is the gap between it and the "dares to self-revolutionize" type of company Baillie Gifford favors.

  More informative is "how it treats mistakes and bad news," and we happen to have a fresh, load-bearing real sample. In December 2023, CooperSurgical voluntarily recalled a batch of embryo culture medium due to a severe magnesium deficiency, causing widespread embryo loss and affecting about 20,000 families worldwide; the complaint alleges it kept producing even as the magnesium hopper on the assembly line ran dry, and did not directly notify affected patients. This is a serious quality-management failure, not a matter of luck, and it must cost points.

  But the test of "bad-news handling" is what follows. Over more than two years, the company's approach has been pragmatic and positive: in FY2026 Q2 it recognized a one-time net pre-tax litigation charge of $271.6 million (a $324.1 million liability accrual, partly offset by $52.5 million of insurance recoveries), making the balance-sheet uncertainty concrete all at once; this turned the quarter's GAAP diluted EPS to -$0.40, and the company did not hide it. More important, the company announced it had reached settlement agreements on the vast majority of recall-related claims, clearing obstacles to advancing the strategic review. The market gave positive feedback to this "clear the bad debt in one go, turn uncertainty into certainty" approach: the stock jumped after Q2 results beat and the litigation path became clearer. Worth noting, at the time of writing (May 24), the report treated the HMRC tax dispute as the main tail risk and said little about the progress of handling this IVF recall, whereas this early-June settlement + accrual is precisely a materialization and largely clearing of the report's "legal and tax tail risk" concern.

  Putting both sides together: the pre-event quality-control failure exposed CooperSurgical's uneven operating quality (which also confirms the report's consistent reservations about this segment); the aftermath handling, transparent accrual, proactive settlement, no dithering, shows that in the face of bad news, management is rational and solution-oriented rather than covering up. This "wrap it up decisively when something goes wrong" discipline, plus subsequently putting this problem business up for sale in its entirety, shows the company has a degree of error-correction and subtraction capability.

  Conclusion: self-disruption/reinvention DNA is not Cooper's strong suit, but fortunately the core business does not rely on it to survive; and the way it treats mistakes and bad news, making it concrete in one go, settling proactively, and immediately divesting the problem asset, is a rare positive signal in this set of answers, worthy of the report's above-passing assessment that "management disclosure is acceptable, governance framework adequate." But remember: even the best "handling" only contains the cost of an avoidable quality accident, and cannot be dressed up as a virtue.

  Jun 11, 2026
• QDoes management (especially the founder) have long-term vision and interests deeply bound to the company? Are they willing to sacrifice current profit for five to ten years out?4/10

  A

  Not deeply bound. Cooper is a mature company led by professional managers, with no sitting founder and relatively low insider ownership: governance framework and disclosure are adequate, and institutional-level alignment is acceptable, but the ownership-level "in the same boat" degree is only moderate; and as for "whether it is willing to sacrifice current profit for five to ten years out," it has indeed made some long-term-oriented trade-offs, but neither the discipline nor the intensity rises to the founder-style long-termism Baillie Gifford favors.

  First, pin down the degree of alignment with first-hand data. This is not a founder company; the CEO is professional manager Albert G. White III. Per the 2026 proxy statement cited by the report, the CEO holds about 1.945 million shares, roughly 1%, and all current directors and officers together hold about 4.064 million shares, roughly 2.08%. For context, Cooper's current market cap is about $13.2 billion (see the unified anchor below), so the CEO's 1% corresponds to a nominal market value over $100 million, not a small sum, but proportionally far from "net worth deeply tied to the company's fate." Institutionally, the company has raised ownership requirements: the CEO must hold stock worth 6x annual salary, and other C-level executives and division presidents were raised to 3x annual salary, with disclosure that all NEOs are in compliance; there is also a compensation clawback policy. These are all positive governance mechanisms, but they are essentially "forced alignment by rules," not the natural owner mindset of a founder.

  Next, whether the incentives point to long-term value. Pay is tied to revenue, Non-GAAP EPS, free cash flow, and Non-GAAP operating profit; the report judges this "shows the board does care about cash flow, not just accounting earnings," which is the good side; but it also means incentives lean toward "growth + adjusted profit" rather than pure compounding of per-share intrinsic value. Two details reveal that "the board is not extremely restrained": per the report, FY2025 CEO total compensation was about $16.05 million, and the PSUs granted in 2023 settled at the 200% cap in 2026 and were paid in cash, generous, hardly a stringent long-term discipline.

  "Whether it will sacrifice current profit for the long term," the evidence cuts both ways. There are two pieces of positive evidence: first, in December 2023 the company proactively stopped its semi-annual dividend, keeping cash in the business for reinvestment and deleveraging, which from a long-term owner's standpoint is an acceptable or even correct trade-off; second, the most telling long-term move right now, management launching a formal strategic review and pushing to sell the weaker but still revenue-contributing CooperSurgical (about one-third of FY2025 revenue) to simplify the business and unlock long-term value, preferring to sacrifice scale and short-term revenue for higher capital-return quality, is a decision with long-term vision.

  But the negative evidence is equally hard: capital-allocation discipline is mediocre, and buybacks lack price discipline. The report calculates it clearly: per the report, FY2025 repurchased 4.1 million shares at an average of about $69.30, and FY2026 Q1 repurchased at an average of about $82.04; FY2026 Q2 continued to repurchase $13.10 million at an average of about $75.84, while the stock was at one point only around $62. For a company that pays no dividend and relies on internal capital allocation, repeatedly buying back at prices well above the lows shows precisely that it "executes whenever authorized," lacking contrarian and valuation discipline; this is far from the owner mindset of "counting every penny for long-term shareholders."

  Conclusion: management is honest, disclosure is full, the governance framework is adequate, and it has made long-term-oriented decisions such as ending the dividend and selling a weak asset, worthy of the report's "Management and Capital Allocation 3/5" score; but with no sitting founder, low insider ownership, and buybacks lacking price discipline, it is a case of "acceptable institutional alignment, average ownership and mindset alignment." By Baillie Gifford's standard, this is not the deeply bound type of team where a founder stakes their entire net worth and dares to sharply sacrifice current profit for ten years out; it is a competent, rational team of professional managers who are only "moderately in the same boat" as shareholders.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and free of reliance on harming society and regulation?6/10

  A

  If it disappeared tomorrow, customers would miss it to a degree, but it is not irreplaceable; this is an "important but replaceable" oligopoly business. Its growth model is broadly sustainable and does not rely on harming society, but CooperSurgical's embryo-culture-medium recall is precisely a counterexample of "product quality harming the most vulnerable customers," a reminder that this business's social and regulatory bottom line cannot be allowed to fail.

  First, indispensability. On the contact-lens side, CooperVision is a stable, high-complexity supplier: for complex fittings such as astigmatism, presbyopia, and pediatric myopia management, patients and doctors are reluctant to switch once a fit succeeds (the report judges switching costs "moderate-to-strong"), and MiSight, as the only FDA-approved lens in the U.S. to slow myopia progression in children, has almost no equivalent substitute in the near term for families using it to control their children's myopia; these customers would genuinely miss it. But to be honest: in bulk categories like ordinary dailies/monthlies, the industry is a four-way oligopoly of Johnson & Johnson Vision, Alcon, CooperVision, and Bausch + Lomb, with the top three together holding about 65%, and if Cooper disappeared its share would be quickly absorbed by rivals; end patients could simply switch to another brand's lenses, so the pain would be limited. So its indispensability is "strong in high-end niches, weak in bulk categories," overall an "important supplier" rather than "irreplaceable infrastructure." The CooperSurgical side is similar: fertility consumables and women's-health devices have clinical stickiness, but facing professional rivals such as Vitrolife, they are equally replaceable.

  Next, the dual sustainability. First question, "does the growth model harm society": in the main it is positive; selling contact lenses, doing pediatric myopia control, and making assisted-reproduction consumables meet real, essential, socially beneficial demand for vision health and childbearing, with global myopia prevalence approaching 50% by 2050 and roughly one in six people of reproductive age experiencing infertility at some point in their lives; this is a business that helps people solve problems rather than creating them. But that counterexample must be put on the table: in December 2023, CooperSurgical's embryo culture medium was recalled due to a magnesium deficiency, causing widespread embryo loss and affecting about 20,000 families worldwide, precisely a live case of "product quality harming the most vulnerable customers"; it shows that the sustainability of this business depends heavily on quality and compliance execution, and once execution fails it directly harms people and rebounds on the company. On the positive side, the company subsequently recognized a one-time $271.6 million charge and reached settlement on the vast majority of claims, and put this once-troubled asset up for sale, a responsible wrap-up.

  Second question, "does it rely on regulatory arbitrage or cross regulatory red lines": it does not; on the contrary, it has a positive structure highly dependent on compliance. The report makes clear that nearly all of the company's products operate under medical-device regulatory systems such as FDA, EU MDR, CLIA, and IVD, and regulation is one source of its moat (approval barriers), not something it seeks to evade; this is entirely different from businesses that profit from regulatory gray zones or by harming consumers. The tail that needs continuous watching is the HMRC tax dispute the report names (around £0 to £71.7 million plus interest in an unfavorable scenario, per the report and the latest filings), but this is a tax dispute, not "making money by harming society."

  Conclusion: customers would genuinely miss it in the high-end, professional, and myopia-management niches, but in bulk categories it is an "important supplier replaceable by oligopoly peers," hardly irreplaceable. The growth model is broadly sustainable, meets real social demand, and is built on compliance rather than regulatory arbitrage; that is a positive mark. But the IVF recall reminds us that this business's social license rests on zero tolerance in quality and safety, and once that fails, it harms precisely the customers who trust it most. On balance, it passes the "does not grow by harming society" test, but its "indispensability" is only moderate.

  Jun 11, 2026
• QWhat are this business's unit economics (gross margin, incremental returns)? Do they improve or worsen at scale? Where does the money earned go?6/10

  A

  Unit economics are above-average but not extreme: gross margin is high (about 66%–68%), with real pricing power and operating leverage, and margins "improve slightly" as scale grows; but incremental returns on capital are diluted by M&A-created goodwill, amortization, and continued capacity expansion, so "good business" does not automatically equal "high company-wide returns on capital." The money earned goes mainly to reinvestment, deleveraging, and buybacks, and the biggest blemish is that buybacks lack price discipline.

  First, the gross-margin and operating-leverage layer, where Cooper is a top student. FY2026 Q2 gross margin was about 68%, and the report records it as long stable in the 65%–67% band, showing it is not an extremely capital-light, infinitely margin-expanding software business, but as a medical-device business with manufacturing characteristics it is already excellent. More important, the operating leverage from scale is real: Q2 non-GAAP operating margin was about 27%, up 260 basis points year over year, with margins still rising even as revenue grew 8%; this is exactly the evidence of "bigger scale, better unit economics." So at the product and operating level, each incremental dollar of revenue does bring above-average marginal profit, especially for CooperVision.

  But the other layer of unit economics, incremental returns on capital, is the soft spot the report repeatedly warns about. Lay out the accounting returns: the report cites StockAnalysis's current TTM ROE of about 4.87% and ROIC of about 4.34%, clearly low by "great company" standards. Two layers of correction are needed here: first, the large deferred tax asset the company recognized in 2021 inflated book equity, and historical M&A piled up large amounts of goodwill and intangibles, systematically lowering book returns on a goodwill-inclusive basis; second, the latest quarter's GAAP figures were further depressed by the $271.6 million IVF litigation accrual (GAAP EPS turned to -$0.40 for the quarter, a one-time item, not operational deterioration). Even stripping out these distortions, the report's core thesis still holds: CooperVision is a high-quality asset, but the whole company is diluted by CooperSurgical's amortization, goodwill, and M&A-tied capital; "good business" has not automatically translated into "high company-wide returns on capital." This is a textbook manifestation of a mode of scaling (via M&A rather than pure organic growth) dragging down incremental returns.

  Where does the money earned go? The report lays it out clearly: the company already stopped its dividend in December 2023 (per the report, no dividend was paid in FY2024 or FY2025), and cash flows mainly to four places: reinvestment in capacity and R&D, M&A, deleveraging, and buybacks. The problem centers on buybacks: FY2026 Q2 repurchased $13.10 million at an average of about $75.84, while the stock was at one point only around $62, and the report records FY2025/FY2026 Q1 average prices of about $69.30/$82.04; for a company that pays no dividend and relies on internal capital allocation, buying back long-term at prices well above the lows shows mediocre capital-allocation discipline.

  A big move that is improving unit economics: the company launched a strategic review and is pushing for an outright sale of the return-dragging CooperSurgical, with most proceeds likely going to buybacks. If it goes through, what remains is the CooperVision standalone with better unit economics and returns on capital, and the company-wide ROIC structure will improve markedly; this amounts to repairing incremental returns on capital by subtraction.

  Conclusion: product-layer unit economics (gross margin + operating leverage) are above-average and improve with scale, and pricing power and margin expansion are real strengths; but capital-layer incremental returns are diluted by M&A, goodwill, and capacity expansion, and company-wide ROE/ROIC are low, the source of the report's judgment that it is "solid at the operating level, mediocre company-wide." The money goes mainly to reinvestment, deleveraging, and buybacks, and the lack of buyback price discipline is a demerit. If the CooperSurgical divestiture lands, it is a key step in realigning "good business" with "good returns on capital," and it is the biggest improvement option for this business's unit economics going forward.

  Jun 11, 2026
• QWhat conditions must simultaneously hold for it to rise fivefold in ten years? Are these conditions realistic? What expectations does today's share price imply?2/10

  A

  A fivefold rise in ten years is, for Cooper, a multi-condition equation extremely hard to satisfy all at once, with low real-world odds; and today's roughly $67.69 share price no longer implies "a deeply undervalued bargain." It implies that the market broadly accepts it as a high-quality, steadily growing good company, with an insufficient margin of safety; this is the core of why the report gives "Watch" rather than "Buy."

  First, translate "fivefold" into hard metrics. As of the June 10, 2026 close, COO was about $67.69, with a market cap of about $13.2 billion (the unified price anchor, shared by all 10 questions in this piece). A fivefold rise in ten years means a share price CAGR of about 17.5% and a market cap reaching about $66 billion. For this to hold, the following conditions must materialize almost simultaneously:

  • Revenue: it must go from about FY2026 guidance of $4.285–4.321 billion to nearly double or more over ten years, i.e., about 8%–10% annualized without losing pace, while the company's current organic growth guidance is only 3.5%–4.5%, requiring it to double its growth rate for the long term.
  • Profit: operating margin must keep expanding significantly from an already high base (Q2 non-GAAP operating margin about 27%, already up 260bp year over year), so that EPS growth outpaces revenue.
  • Returns on capital: it must substantially lift the company-wide ROIC of about 4.34% soft spot the report repeatedly names, most likely realized by divesting CooperSurgical.
  • Valuation: the market must also be willing to keep awarding it a high multiple (no valuation compression).
  • Execution: over ten years, myopia management (MiSight) keeps scaling, silicone-hydrogel share keeps rising, and no major regulatory/product/litigation black swan occurs.

  Of these five conditions, each on its own is not absurd, but the joint probability of "all holding simultaneously for ten straight years" is low; especially the two of long-term doubling of the growth rate and a large improvement in returns on capital pull against each other (high growth often relies on M&A, and M&A is precisely what drags down ROIC). The report's corresponding judgment is that the expected annualized return is only 5%–7% in the base scenario and only 8%–10% even in the bull case, an order-of-magnitude gap from "the 17.5% a fivefold requires." So the honest conclusion is: the conditions needed for a fivefold in ten years are unrealistically high; this is not a candidate five-bagger.

  Now, what expectations does today's share price imply? Cross-check with two measures:

  First, absolute valuation. The report's discounted-owner-earnings intrinsic-value ranges are bear $42–50, base $50–60, and bull $60–70. The current $67.69 already sits at the upper edge of the base range, close to the bull range; that is, the market's pricing already embeds a fairly full expectation of "the business continuing to grow steadily + the Vision moat being realized," with almost no room left for error. The report's ideal buy price is $40–48 (leaving a 20%–30% cushion against base-case value), and the current price is about 40% above it.

  Second, relative valuation. The GAAP TTM P/E of about 57x looks scary, but this is a distorted figure after that $271.6 million one-time IVF litigation accrual in Q2 severely depressed profit, and cannot be used directly; it is a textbook one-time-item distortion of the P/E. On the more operationally representative FY2026 non-GAAP EPS guidance midpoint of about $4.62, the forward P/E is about 14.6x; for a medical-device leader with 68% gross margin and 10 consecutive quarters of beats, this forward multiple is no bubble, and can even be called reasonable and on the mild side. This is exactly the basis for analysts giving "Buy/Hold" with a target price a bit over $80.

  Combining the two measures: the market prices COO as "a reasonably priced high-quality compounder," treating it neither as a bargain (no deep discount) nor as a five-bagger growth stock (the forward multiple is mild and does not front-run high growth). The implied expectation is "steadily earning mid-to-high-single-digit organic growth + potential value release from the divestiture," not "a nonlinear ten-year explosion."

  Conclusion: the multiple conditions needed for a fivefold in ten years are almost impossible to hold simultaneously; COO is not a five-bagger name. Today's share price implies "a good company at a fair price," slightly expensive on owner earnings with an insufficient margin of safety (hence the report's "Watch"), and roughly reasonable on forward earnings. What it offers long-term holders is steady compounding and a value-release option from divesting Surgical, not the imagination of a fivefold gain.

  Jun 11, 2026
• QWhy has the market not yet realized all this? Is it that it cannot understand, looks down on it, or cannot see far enough? What will become the "narrative inflection point"?3/10

  A

  Frankly, this question must be answered half in reverse for COO: the market does not "fail to understand, look down on, or see far enough" on its core business; it is a well-covered, broadly fairly priced large-cap leader, with no huge perception gap of the "whole market misjudging" kind. The only thing not yet fully priced in by the market is a single directional perception gap: the value that could be released by realigning "good business" with "good returns on capital" through selling CooperSurgical, and this is precisely the most ready-made "narrative inflection point."

  First, make clear "why it is not undervalued"; this is the honest premise. COO's market cap is about $13.2 billion (the unified anchor), with coverage by 11-plus brokers, a consensus of "Buy/Hold," and a target price a bit over $80, and 10 consecutive quarters of beats. Its business (contact-lens oligopoly + assisted reproduction), moat (concentrated in Vision), and soft spot (Surgical dragging ROIC) have all been discussed repeatedly by the report and the sell side, and its pricing sits at the reasonable upper edge of the report's intrinsic-value range; this is not a "dusty" stock. So the classic undervaluation narrative of "cannot understand / looks down on / cannot see far" basically does not hold for it; the report gives "Watch" because the market's pricing is already fairly full and the margin of safety is insufficient, not because the market wrongly killed a bargain. In other words, there is no bargain to be picked up here; this must be admitted first, and one cannot fabricate a nonexistent perception gap just to fit Baillie Gifford's "why the market has not realized" framework.

  So where is the only genuine, "cannot see far"-leaning perception gap? It lies in the market possibly not yet fully pricing in the force of SOTP (sum-of-the-parts) value release. The report's third valuation method already points it out: much of COO's book equity is goodwill, M&A intangibles, and deferred tax assets, and after stripping them out the "hard equity" is very thin; its value lies entirely in future cash flow and the moat, while the high-quality CooperVision asset has long been diluted by CooperSurgical's low returns. The market has priced it as a "composite" package in the past, and has not fully priced in that "once split apart, the Vision standalone should command a higher valuation."

  And this perception gap is being activated by a concrete catalyst, which is the narrative inflection point. In December 2025 the company launched a formal strategic review and simultaneously changed its board chair, and in the latest quarter made clear it is in talks with multiple parties to sell CooperSurgical, leaning toward an outright sale, with most proceeds likely going to buybacks. Alongside this step, the company also took a one-time $271.6 million accrual for the IVF recall litigation and reached settlement on the vast majority of claims, effectively clearing the biggest uncertainty before selling this asset and removing obstacles to the deal. The market has begun to price this in: the stock jumped after Q2 results beat and the litigation path became clearer, but there is also disagreement (Wells Fargo cut its target price on the uncertainty of the CSI sale), showing this is not yet fully priced in and remains an open perception gap. Worth noting, at the time of writing on May 24, the report focused on "Surgical dragging, buybacks not cheap" and said little about this imminent divestiture deal, whereas the early-June developments turned the report's biggest uncertainty of "whether Surgical can improve return quality" into an event-driven catalyst with a clear timetable.

  What will become the true narrative inflection point (the signal that triggers re-rating)? The most direct is the formal landing of the CooperSurgical sale: the transaction price, whether it is an outright sale, the use of proceeds (buybacks vs. deleveraging), and the standalone margin and ROIC disclosed by the remaining CooperVision standalone. Once the market sees "post-divestiture, the Vision standalone's ROIC lifts markedly, and its valuation should benchmark against a purer eye-care platform (such as Alcon)," the narrative will switch from "a composite dragged down by Surgical" to "a high-purity vision-health leader," which is COO's most likely value re-rating path. Conversely, if the deal falls through, the sale price disappoints, or myopia-management scaling falls short, this logic is falsified and the stock will give back this portion of expectations.

  Conclusion: COO is not a cheap stock wrongly killed because "the market cannot understand / looks down on / cannot see far"; it is well-covered and fairly priced, which must be honestly admitted. Its only genuine, positively directional perception gap is that the market has not yet fully priced in the value-release force of "divesting CooperSurgical and realigning good business with good returns on capital"; and the CSI sale + litigation clearing now under way is the most ready-made, most likely narrative inflection point to realize this gap. For long-term trackers, the landing of this event (rather than short-term price swings) is the real variable worth watching closely.

  Jun 11, 2026